Literature DB >> 16550455

Optimal design for multivariate response pharmacokinetic models.

Ivelina Gueorguieva1, Leon Aarons, Kayode Ogungbenro, Karin M Jorga, Trudy Rodgers, Malcolm Rowland.   

Abstract

We address the problem of designing pharmacokinetic experiments in multivariate response situations. Criteria, based on the Fisher information matrix, whose inverse according to the Rao-Cramer inequality is the lower bound of the variance-covariance matrix of any unbiased estimator of the parameters, have previously been developed for univariate response for an individual and a population. We extend these criteria to design individual and population studies where more than one response is measured, for example, when both parent drug and metabolites are measured in plasma, multi-compartment models, where measurements are taken at more than one site, or when drug concentration and pharmacodynamic data are collected simultaneously. We assume that measurements made at distinct times are independent, but measurements made of each concentration are correlated with a response variance-covariance matrix. We investigated a number of optimisation algorithms, namely simplex, exchange, adaptive random search, simulated annealing and a hybrid, to maximise the determinant of the Fisher information matrix as required by the D-optimality criterion. The multiresponse optimal design methodology developed was applied in two case studies, where the aim was to suggest optimal sampling times. The first was a restrospective iv infusion experiment aimed to characterise the disposition kinetics of tolcapone and its two metabolites in healthy volunteers. The second was a prospective iv bolus experiment designed to estimate the tissue disposition kinetics of eight beta-blockers in rat.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16550455     DOI: 10.1007/s10928-006-9009-1

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  15 in total

1.  Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs.

Authors:  S Retout; S Duffull; F Mentré
Journal:  Comput Methods Programs Biomed       Date:  2001-05       Impact factor: 5.428

2.  Further developments of the Fisher information matrix in nonlinear mixed effects models with evaluation in population pharmacokinetics.

Authors:  Sylvie Retout; France Mentré
Journal:  J Biopharm Stat       Date:  2003-05       Impact factor: 1.051

3.  Simultaneous vs. sequential analysis for population PK/PD data II: robustness of methods.

Authors:  Liping Zhang; Stuart L Beal; Lewis B Sheinerz
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-12       Impact factor: 2.745

4.  Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance.

Authors:  Liping Zhang; Stuart L Beal; Lewis B Sheiner
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-12       Impact factor: 2.745

5.  The use of a modified Fedorov exchange algorithm to optimise sampling times for population pharmacokinetic experiments.

Authors:  Kayode Ogungbenro; Gordon Graham; Ivelina Gueorguieva; Leon Aarons
Journal:  Comput Methods Programs Biomed       Date:  2005-08-31       Impact factor: 5.428

6.  A program for the optimum design of pharmacokinetic, pharmacodynamic, drug metabolism and drug-drug interaction models.

Authors:  Gordon Graham; Ivelina Gueorguieva; Kelly Dickens
Journal:  Comput Methods Programs Biomed       Date:  2005-04-22       Impact factor: 5.428

Review 7.  Optimal statistical design for toxicokinetic studies.

Authors:  D A Beatty; W W Piegorsch
Journal:  Stat Methods Med Res       Date:  1997-12       Impact factor: 3.021

8.  Experimental design and efficient parameter estimation in preclinical pharmacokinetic studies.

Authors:  E I Ette; C A Howie; A W Kelman; B Whiting
Journal:  Pharm Res       Date:  1995-05       Impact factor: 4.200

9.  Tissue distribution of basic drugs: accounting for enantiomeric, compound and regional differences amongst beta-blocking drugs in rat.

Authors:  Trudy Rodgers; David Leahy; Malcolm Rowland
Journal:  J Pharm Sci       Date:  2005-06       Impact factor: 3.534

10.  Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide.

Authors:  C A Peloquin; G S Jaresko; C L Yong; A C Keung; A E Bulpitt; R W Jelliffe
Journal:  Antimicrob Agents Chemother       Date:  1997-12       Impact factor: 5.191

View more
  11 in total

1.  Adaptive optimal design for bridging studies with an application to population pharmacokinetic studies.

Authors:  Lee Kien Foo; Stephen Duffull
Journal:  Pharm Res       Date:  2012-02-14       Impact factor: 4.200

2.  Serial correlation in optimal design for nonlinear mixed effects models.

Authors:  Joakim Nyberg; Richard Höglund; Martin Bergstrand; Mats O Karlsson; Andrew C Hooker
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-03-14       Impact factor: 2.745

3.  An example of optimal phase II design for exposure response modelling.

Authors:  Alan Maloney; Marloes Schaddelee; Jan Freijer; Walter Krauwinkel; Marcel van Gelderen; Philippe Jacqmin; Ulrika S H Simonsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-09-25       Impact factor: 2.745

4.  Methods and software tools for design evaluation in population pharmacokinetics-pharmacodynamics studies.

Authors:  Joakim Nyberg; Caroline Bazzoli; Kay Ogungbenro; Alexander Aliev; Sergei Leonov; Stephen Duffull; Andrew C Hooker; France Mentré
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

5.  Simultaneous versus sequential optimal design for pharmacokinetic-pharmacodynamic models with FO and FOCE considerations.

Authors:  J M McGree; J A Eccleston; S B Duffull
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-02-18       Impact factor: 2.745

6.  A general model-based design of experiments approach to achieve practical identifiability of pharmacokinetic and pharmacodynamic models.

Authors:  Federico Galvanin; Carlo C Ballan; Massimiliano Barolo; Fabrizio Bezzo
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-06-04       Impact factor: 2.745

Review 7.  Combining the 'bottom up' and 'top down' approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data.

Authors:  Nikolaos Tsamandouras; Amin Rostami-Hodjegan; Leon Aarons
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

8.  D-optimal designs for parameter estimation for indirect pharmacodynamic response models.

Authors:  Leonid A Khinkis; Wojciech Krzyzanski; William J Jusko; William R Greco
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-11-11       Impact factor: 2.745

9.  Population Fisher information matrix and optimal design of discrete data responses in population pharmacodynamic experiments.

Authors:  Kayode Ogungbenro; Leon Aarons
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-06-10       Impact factor: 2.745

10.  Whole body physiologically based modelling of β-blockers in the rat: events in tissues and plasma following an i.v. bolus dose.

Authors:  S Y A Cheung; T Rodgers; L Aarons; I Gueorguieva; G L Dickinson; S Murby; C Brown; B Collins; M Rowland
Journal:  Br J Pharmacol       Date:  2017-12-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.